Following USA – WHO Reports on Wave of Acute Childhood Hepatitis in the UK and Ireland 18/04/2022 Elaine Ruth Fletcher The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland. That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of […] Continue reading -> Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Shanghai Cases Surge as China Ramps Up “Zero-Tolerance” Policy to COVID-19 15/04/2022 Raisa Santos China’s financial hub Shanghai continues to see rising COVID-19 cases despite the country’s attempts at a “no COVID” policy. The city reported over 27,000 coronavirus cases on Thursday, a new high, following Chinese President Xi Jinping’s announcement a day earlier reinforcing the zero-tolerance approach to COVID. “Prevention and control work cannot be relaxed,” Xi said […] Continue reading -> With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Latest Peer-Reviewed Study Underlines Benefits of Second COVID Booster for Older People 18/04/2022 Maayan Hoffman The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters. The study, conducted by Israel’s […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Shanghai Cases Surge as China Ramps Up “Zero-Tolerance” Policy to COVID-19 15/04/2022 Raisa Santos China’s financial hub Shanghai continues to see rising COVID-19 cases despite the country’s attempts at a “no COVID” policy. The city reported over 27,000 coronavirus cases on Thursday, a new high, following Chinese President Xi Jinping’s announcement a day earlier reinforcing the zero-tolerance approach to COVID. “Prevention and control work cannot be relaxed,” Xi said […] Continue reading -> With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Shanghai Cases Surge as China Ramps Up “Zero-Tolerance” Policy to COVID-19 15/04/2022 Raisa Santos China’s financial hub Shanghai continues to see rising COVID-19 cases despite the country’s attempts at a “no COVID” policy. The city reported over 27,000 coronavirus cases on Thursday, a new high, following Chinese President Xi Jinping’s announcement a day earlier reinforcing the zero-tolerance approach to COVID. “Prevention and control work cannot be relaxed,” Xi said […] Continue reading -> With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Shanghai Cases Surge as China Ramps Up “Zero-Tolerance” Policy to COVID-19 15/04/2022 Raisa Santos China’s financial hub Shanghai continues to see rising COVID-19 cases despite the country’s attempts at a “no COVID” policy. The city reported over 27,000 coronavirus cases on Thursday, a new high, following Chinese President Xi Jinping’s announcement a day earlier reinforcing the zero-tolerance approach to COVID. “Prevention and control work cannot be relaxed,” Xi said […] Continue reading -> With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
With COVID Vaccine Supply Outstripping Vaccination Rates, Pharma Giants Question Pursuit of IP Waiver 13/04/2022 Kerry Cullinan Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading -> COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
COVID-19 Pandemic Still Poses a Danger Despite Lower Case Rates, Says WHO 13/04/2022 Aishwarya Tendolkar COVID-19 affiliated deaths last week were the lowest on record globally since the pandemic began two years ago. But the World Health Organisation (WHO) today emphasized that the pandemic remains a public health emergency and we must not drop our guards. “This is the moment to work even harder to save lives,” said Dr Tedros […] Continue reading -> Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Health Matters: Around the World of Public Health in Audio 13/04/2022 Maayan Hoffman After Dr Garry Aslanyan became an avid follower of podcasts, he realized there was a dearth of material from the genre in his own global health field. So he set out to fill that gap with a new series featuring public health professionals and policymakers from around the world who have made a difference – […] Continue reading -> Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Championing Health Equity in South Africa – Global Health Matters Podcast Series 13/04/2022 Editorial team The second season of the Global Health Matters podcast series kicks off with a close-up look at South Africa’s health equity initiatives and champions. Health Policy Watch will be featuring episodes from the series throughout the coming year as part of a TDR-supported series. As the world commits to equitable access to medicines and vaccines, […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Artificial Intelligence ‘Boot Camp’ Aims to Accelerate Drug Discovery 08/04/2022 Maayan Hoffman TEL AVIV – Ninety percent of drug candidates fail in clinical trials because of unexpected safety issues or lack of efficacy in human subjects, according to Noga Yerushalmi, Investment Director at M Ventures, the strategic, corporate venture capital arm of Merck. There have been dramatic improvements in omics technologies – that is the collective technologies […] Continue reading -> Posts navigation Older postsNewer posts